Business
PDMR Dealings
Oxford Biomedica PLC (OXB) announced that Non-Executive Director Kay Davies inadvertently purchased 4,563 shares at £4.36 per share on August 11, 2025, and subsequently sold the same number at £5.0040 per share on August 18, 2025, due to an administrative error by her financial advisors. The transaction was reversed, and any profit will be donated to charity. The initial purchase and subsequent sale were executed on the London Stock Exchange's Main Market (XLON). The shares are Ordinary Shares of 50 pence each (ISIN: GB00BDFBVT43). The total cost of the purchase was £19,894.68, and the total proceeds from the sale were £22,833.34. Disclaimer*
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \nPDMR Dealing\n \nOxford, UK - 22 August 2025: OXB (LSE: OXB) (the \"Company\"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kay Davies, a Non-Executive Director of the Company, purchased 4,563 shares at £4.36 per share on 11 August 2025 and disposed the same number (4,563) at £5.0040 per share on 18 August 2025.\nThe purchase of shares occurred during a closed period as a result of an administrative error by the PDMR's financial advisers. Accordingly, the transaction was executed on behalf of the PDMR without her immediate knowledge. The transaction was subsequently reversed, with the same number of shares sold as had originally been purchased. Upon being informed of the trade, the PDMR promptly escalated the matter to OXB, who in turn notified the FCA without delay.\n \nAs a gesture of goodwill, the PDMR has confirmed that any gains arising from the trade will be donated to a charity of their choice.\n \nThe below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.\n \n\n\n\n\n1.\n\n\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\n\n\n\n\na)\n\n\nName\n\n\nKay Davies\n\n\n\n\n2.\n\n\nReason for the notification\n\n\n\n\na)\n\n\nPosition/status\n\n\nNon-Executive Director\n\n\n\n\nb)\n\n\nInitial notification/ amendment\n\n\nInitial Notification\n\n\n\n\n3.\n\n\nDetails of the Issuer\n\n\n\n\na)\n\n\nFull name of the entity\n\n\nOxford Biomedica plc\n\n\n\n\nb)\n\n\nLEI code\n\n\n213800S1GVQNXQ15K851\n\n\n\n\n4.\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na)\n\n\nDate of the transaction\n\n\n2025-08-11\n\n\n\n\nb)\n\n\nDescription of the financial instrument\n\n\nOrdinary Shares of 50 pence each\n \n\n\n\n\nc)\n\n\nIdentification code\n\n\nISIN: GB00BDFBVT43\n\n\n\n\nd)\n\n\nNature of the transaction\n\n\nPurchase of Shares\n\n\n\n\ne)\n\n\nPlace of the transaction\n\n\nLondon Stock Exchange, Main Market (XLON)\n\n\n\n\nf)\n\n\nCurrency\n\n\nGBP - British pound\n\n\n\n\ng)\n\n\nPrice(s) and volumes(s)\n \n\n\n\n\n\n\nPrice(s)\n\n\nVo...